Rangaswami, Janani

Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association

Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation

Diabetes, Cardiovascular Risks, and LipoproteinsChronic Kidney Disease and Diabetes

Cited by 2,208

A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association

Ndumele, C. E., Neeland, I. J., Tuttle, K. R., Chow, S. L., Mathew, R. O., Khan, S. S., Coresh, J., Baker-Smith, C. M., Carnethon, M. R., Després, J.-P., et al. (2023) · Circulation

Diabetes, Cardiovascular Risks, and LipoproteinsChronic Kidney Disease and Diabetes

Cited by 1,405

Development and validation of the American Heart Association’s PREVENT equations

Khan, S. S., Matsushita, K., Sang, Y., Ballew, S. H., Grams, M. E., Surapaneni, A., Blaha, M. J., Carson, A. P., Chang, A. R., Ciemins, E., et al. (2024) · Circulation

Health Promotion and Cardiovascular PreventionCardiovascular Health and Risk Factors

Cited by 1,234

Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association

Khan, S. S., Coresh, J., Pencina, M. J., Ndumele, C. E., Rangaswami, J., Chow, S. L., Palaniappan, L. P., Sperling, L. S., Virani, S. S., Ho, J. E., et al. (2023) · Circulation

Health Promotion and Cardiovascular PreventionDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 797

Metabolic syndrome

Neeland, I. J., Lim, S., Tchernof, A., Gastaldelli, A., Rangaswami, J., Ndumele, C. E., Powell-Wiley, T. M., & Després, J.-P. (2024) · Nature Reviews Disease Primers

Diabetes, Cardiovascular Risks, and LipoproteinsAdipokines, Inflammation, and Metabolic Diseases

Cited by 463

Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association

Rangaswami, J., Bhalla, V., de Boer, I. H., Staruschenko, A., Sharp, J. A., Singh, R. R., Lo, K. B., Tuttle, K., Vaduganathan, M., Ventura, H., et al. (2020) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 192

2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome

Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC

Diabetes, Cardiovascular Risks, and LipoproteinsChronic Kidney Disease and Diabetes

Cited by 90

Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease

Tuttle, K. R., Wong, L., St. Peter, W., Roberts, G., Rangaswami, J., Mottl, A., Kliger, A. S., Harris, R. C., Gee, P. O., Fowler, K., et al. (2022) · Clinical Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 87